TriSalus Life Sciences, Inc.
TLSIW- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001826667
No open-market purchases or sales by TriSalus Life Sciences, Inc. insiders were filed in the last 90 days; 5 institutions reported holding it in 13F filings for Q2 2026, worth $798.0K in total; no superinvestor holds it.
Other share classesTLSI
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by TriSalus Life Sciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for TriSalus Life Sciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Patience David | Chief Financial Officer | 261,107 | Jul 6, 2026 | 4 |
| Szela Mary T | CEO and President | 1,077,683 | Jul 1, 2026 | 5 |
| Marshak Richard | Chief Commercial Officer | 128,319 | Jul 1, 2026 | 4 |
| Marshall Richard Henry | Chief Medical Officer | 90,000 | Jun 29, 2026 | 1 |
| Stansky Michael P | Director | 399,698Indirect | May 18, 2026 | 4 |
| Wahlstrom Mats | Director | 147,555 | May 18, 2026 | 2 |
| Gordon Gary B. | Director | 72,510 | May 18, 2026 | 3 |
| Hicks Kerry R | Director | 542,790 | May 15, 2026 | 1 |
| Matlin David J | Director | 1,323,210 | May 15, 2026 | 2 |
| Valle William | Director | 83,241 | May 15, 2026 | 2 |
| Frankenius Equity AB | 10% Owner | 6,989,748 | Apr 20, 2026 | 1 |
| Cox Bryan F. | Chief of Research | 163,415 | Mar 20, 2026 | 2 |
| Stevens Jennifer | Chief Regulatory Officer | 124,110 | Mar 20, 2026 | 2 |
| Devlin Jodi | Chief of Clinical Operations | 97,364 | Mar 20, 2026 | 2 |
| Murphy Sean | Director | 123,989 | Jun 27, 2025 | 0 |
| Desai Arjun JJ | Director | 247,127 | Jun 27, 2025 | 0 |
| Young James Emmett | Chief Financial Officer | 49,663 | May 21, 2025 | 0 |
| Hyveled Liselotte | Director | 10,040 | Jan 6, 2025 | 0 |
| Martin George Kelly | Director | 247,176Indirect | Sep 10, 2024 | 0 |
| Von Eschenbach Andrew C. | Director | – | Aug 21, 2024 | 0 |
| Singhal Anil K. | Director | – | Aug 21, 2024 | 0 |
| Katz Steven C | CHIEF MEDICAL OFFICER | 68,587 | Feb 14, 2024 | 0 |
| Dewey Christopher C | 10% Owner | 6,249,999 | Jun 27, 2023 | 0 |
| MedTech Acquisition Sponsor LLC | 10% Owner | 6,249,999 | Jun 27, 2023 | 0 |
| Magnetar Financial LLC | 10% Owner | 16,668Indirect | Jun 14, 2023 | 0 |
| Magnetar Capital Partners LP | 10% Owner | 16,668Indirect | Jun 14, 2023 | 0 |
| Supernova Management LLC | 10% Owner | 16,668Indirect | Jun 14, 2023 | 0 |
| Snyderman David J. | 10% Owner | 16,668Indirect | Jun 14, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 19, 2026 (view filing) | May 15 | 4 days | Marshak RichardChief Commercial Officer | SSale | −543 | $2.67 | −$1.45K | −0.4%125.1K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Wahlstrom MatsDirector | PPurchase | +60.0K | $2.53 | +$151.8K | +68.5%147.6K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +410.0K | $2.50 | +$1.02M | +49.4%1.24M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Stansky Michael PDirector | PPurchase | +200.0K | $2.50 | +$500.0K | +100.2%399.7K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Szela Mary TCEO and President | PPurchase | +39.7K | $2.59 | +$102.8K | +3.9%1.07M after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Patience DavidChief Financial Officer | PPurchase | +7.10K | $2.43 | +$17.3K | +2.6%275.8K after | |
| May 18, 2026 (view filing) | May 15 | 3 days | Gordon Gary B.Director | PPurchase | +10.0K | $2.46 | +$24.6K | +16.0%72.5K after | |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Devlin JodiChief of Clinical Operations | SSale | −3.21K | $4.11 | −$13.2K | −3.2%97.4K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Cox Bryan F.Chief of Research | SSale | −3.18K | $4.11 | −$13.1K | −1.9%163.4K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Marshak RichardChief Commercial Officer | SSale | −3.46K | $4.11 | −$14.2K | −3.0%110.4K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-16 | 9 daysLate | Stevens JenniferChief Regulatory Officer | SSale | −3.53K | $4.11 | −$14.5K | −2.8%124.1K after | 3 lots |
| Mar 20, 2026 (view filing) | Mar 11-17 | 9 daysLate | Szela Mary TCEO and President | SSale | −20.3K | $3.91 | −$79.4K | −2.6%753.0K after | 2 lots |
| Feb 23, 2026 (view filing) | Feb 23 | Same day | Patience DavidChief Financial Officer | PPurchase | +3.66K | $4.10 | +$15.0K | +1.4%268.7K after | |
| Feb 23, 2026 (view filing) | Feb 23 | Same day | Gordon Gary B.Director | PPurchase | +9.76K | $4.10 | +$40.0K | New position9.76K after | |
| Feb 23, 2026 (view filing) | Feb 23 | Same day | Valle WilliamDirector | PPurchase | +30.5K | $4.10 | +$125.0K | New position30.5K after | |
| Feb 23, 2026 (view filing) | Feb 23 | Same day | Szela Mary TCEO and President | PPurchase | +30.5K | $4.10 | +$125.0K | +4.1%773.3K after | |
| Feb 23, 2026 (view filing) | Feb 23 | Same day | Stansky Michael PDirector | PPurchase | +243.9K | $4.10 | +$1.00M | +44.9%787.1K after | |
| Feb 23, 2026 (view filing) | Feb 23 | Same day | Stansky Michael PDirector | PPurchase | +117.2K | $4.10 | +$480.5K | +142.1%199.7K after | |
| May 21, 2025 (view filing) | May 19 | 2 days | Cox Bryan F.Chief of Research | SSale | −4.76K | $5.18 | −$24.7K | −3.8%119.4K after | |
| May 21, 2025 (view filing) | May 19 | 2 days | Devlin JodiChief of Clinical Operations | SSale | −4.76K | $5.18 | −$24.7K | −8.3%52.8K after | |
| May 21, 2025 (view filing) | May 19 | 2 days | Marshak RichardChief Commercial Officer | SSale | −6.60K | $5.18 | −$34.2K | −8.7%69.1K after | |
| May 21, 2025 (view filing) | May 19 | 2 days | Stevens JenniferChief Regulatory Officer | SSale | −8.70K | $5.18 | −$45.1K | −10.1%77.6K after | |
| Feb 6, 2025 (view filing) | Feb 5 | 1 day | Young James EmmettChief Financial Officer | PPurchase | +6.00K | $5.65 | +$33.9K | +25.0%30.0K after | |
| Jan 31, 2025 (view filing) | Jan 29-30 | 2 days | Szela Mary TCEO AND PRESIDENT | PPurchase | +10.0K | $5.15 | +$51.8K | +2.3%444.3K after | 2 lots |
| Jan 29, 2025 (view filing) | Jan 27-28 | 2 days | Szela Mary TCEO AND PRESIDENT | PPurchase | +9.54K | $5.27 | +$50.3K | +2.2%434.2K after | 2 lots |
| Jan 29, 2025 (view filing) | Jan 27-28 | 2 days | Murphy SeanChief Manuf, Strategy&Bus Dev. | PPurchase | +30.0K | $5.24 | +$157.2K | +17.9%197.7K after | 2 lots |
| Jan 29, 2025 (view filing) | Jan 27 | 2 days | Young James EmmettChief Financial Officer | PPurchase | +24.0K | $5.40 | +$129.6K | New position24.0K after | |
| Dec 19, 2024 (view filing) | Oct 5 | 75 daysLate | Cox Bryan F.CHIEF SCIENTIFIC & MANUFACT. | SSale | −314 | $4.44 | −$1.39K | −0.4%86.4K after | |
| Dec 19, 2024 (view filing) | Dec 17 | 2 days | Frankenius Equity AB10% Owner | PPurchase | +63.0K | $3.97 | +$250.0K | +1.0%6.23M after | |
| Dec 12, 2024 (view filing) | Dec 10 | 2 days | Desai Arjun JJDirector | SSale | −30.0K | $3.69 | −$110.7K | −10.8%247.1K after | |
| Nov 25, 2024 (view filing) | Nov 22 | 3 days | Wahlstrom MatsDirector, 10% Owner | PPurchase | +5.00K | $4.55 | +$22.8K | +46.6%15.7K after | |
| Nov 22, 2024 (view filing) | Nov 20-21 | 2 days | Wahlstrom MatsDirector, 10% Owner | PPurchase | +10.7K | $4.39 | +$47.1K | New position10.7K after | 2 lots |
| Sep 13, 2024 (view filing) | Sep 12-13 | 1 day | Szela Mary TCEO AND PRESIDENT | PPurchase | +14.8K | $5.09 | +$75.4K | +4.0%384.7K after | 3 lots |
| Sep 12, 2024 (view filing) | Sep 10 | 2 days | Szela Mary TCEO AND PRESIDENT | PPurchase | +5.00K | $4.97 | +$24.9K | +1.4%369.9K after | |
| Sep 10, 2024 (view filing) | Aug 28 | 13 daysLate | Martin George KellyDirector | SSale | −9 | $5.50 | −$49.5 | 0.0%247.2K after |